Pre-clinical lung squamous cell carcinoma mouse models to identify novel biomarkers and therapeutic interventions
- PMID: 37817767
- PMCID: PMC10560855
- DOI: 10.3389/fonc.2023.1260411
Pre-clinical lung squamous cell carcinoma mouse models to identify novel biomarkers and therapeutic interventions
Abstract
Primary lung carcinoma or lung cancer (LC) is classified into small-cell or non-small-cell (NSCLC) lung carcinoma. Lung squamous cell carcinoma (LSCC) is the second most common subtype of NSCLC responsible for 30% of all LCs, and its survival remains low with only 24% of patients living for five years or longer post-diagnosis primarily due to the advanced stage of tumors at the time of diagnosis. The pathogenesis of LSCC is still poorly understood and has hampered the development of effective diagnostics and therapies. This review highlights the known risk factors, genetic and epigenetic alterations, miRNA biomarkers linked to the development and diagnosis of LSCC and the lack of therapeutic strategies to target specifically LSCC. We will also discuss existing animal models of LSCC including carcinogen induced, transgenic and xenograft mouse models, and their advantages and limitations along with the chemopreventive studies and molecular studies conducted using them. The importance of developing new and improved mouse models will also be discussed that will provide further insights into the initiation and progression of LSCC, and enable the identification of new biomarkers and therapeutic targets.
Keywords: animal models; genetic and epigenetic alterations; lung cancer; risk factors; squamous cell carcinoma.
Copyright © 2023 Sahu, Donovan, Paudel, Pickles, Chimankar, Kim, Horvart, Dua, Ieni, Nucera, Bielefeldt-Ohmann, Mazilli, Caramori, Lyons and Hansbro.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures

Similar articles
-
Potentials of lncRNA-miRNA-mRNA networks as biomarkers for laryngeal squamous cell carcinoma.Hum Cell. 2023 Jan;36(1):76-97. doi: 10.1007/s13577-022-00799-x. Epub 2022 Oct 1. Hum Cell. 2023. PMID: 36181662 Review.
-
Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials.Signal Transduct Target Ther. 2022 Oct 5;7(1):353. doi: 10.1038/s41392-022-01200-x. Signal Transduct Target Ther. 2022. PMID: 36198685 Free PMC article. Review.
-
Comparing progression molecular mechanisms between lung adenocarcinoma and lung squamous cell carcinoma based on genetic and epigenetic networks: big data mining and genome-wide systems identification.Oncotarget. 2019 Jun 4;10(38):3760-3806. doi: 10.18632/oncotarget.26940. eCollection 2019 Jun 4. Oncotarget. 2019. PMID: 31217907 Free PMC article.
-
Differential expression of sonic hedgehog in lung adenocarcinoma and lung squamous cell carcinoma.Neoplasma. 2019 Sep;66(5):839-846. doi: 10.4149/neo_2018_181228N1002. Epub 2019 Jun 3. Neoplasma. 2019. PMID: 31167533
-
CD271 is a negative prognostic factor and essential for cell proliferation in lung squamous cell carcinoma.Lab Invest. 2019 Sep;99(9):1349-1362. doi: 10.1038/s41374-019-0246-5. Epub 2019 Apr 24. Lab Invest. 2019. PMID: 31019292
Cited by
-
Silibinin Induces Both Apoptosis and Necroptosis with Potential Anti-tumor Efficacy in Lung Cancer.Anticancer Agents Med Chem. 2024;24(18):1327-1338. doi: 10.2174/0118715206295371240724092314. Anticancer Agents Med Chem. 2024. PMID: 39069713
-
A potential therapeutic strategy based on acute oxidative stress induction for wild-type NRF2/KEAP1 lung squamous cell carcinoma.Redox Biol. 2024 Sep;75:103305. doi: 10.1016/j.redox.2024.103305. Epub 2024 Aug 8. Redox Biol. 2024. PMID: 39137583 Free PMC article.
-
Liposomal encapsulated curcumin attenuates lung cancer proliferation, migration, and induces apoptosis.Heliyon. 2024 Sep 25;10(19):e38409. doi: 10.1016/j.heliyon.2024.e38409. eCollection 2024 Oct 15. Heliyon. 2024. PMID: 39416833 Free PMC article.
-
The Current Molecular and Cellular Landscape of Chronic Obstructive Pulmonary Disease (COPD): A Review of Therapies and Efforts towards Personalized Treatment.Proteomes. 2024 Aug 16;12(3):23. doi: 10.3390/proteomes12030023. Proteomes. 2024. PMID: 39189263 Free PMC article. Review.
References
-
- Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. . The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol (2015) 10(9):1243–60. doi: 10.1097/JTO.0000000000000630 - DOI - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources